C-Myc protein expression indicates unfavorable clinical outcome in surgically resected small cell lung cancer

[1]  Jasmine Chen,et al.  MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat , 2023, Journal of Experimental & Clinical Cancer Research.

[2]  Hiroshige Nakamura,et al.  Clinical significance of MYC family protein expression in surgically resected high‐grade neuroendocrine carcinoma of the lung , 2023, Thoracic cancer.

[3]  B. Döme,et al.  In‐depth proteomic analysis reveals unique subtype‐specific signatures in human small‐cell lung cancer , 2022, Clinical and translational medicine.

[4]  F. Hirsch,et al.  Expression patterns and prognostic relevance of subtype‐specific transcription factors in surgically resected small‐cell lung cancer: an international multicenter study , 2022, The Journal of pathology.

[5]  L. Rojkó,et al.  Nationwide lung cancer screening with low-dose computed tomography: implementation and first results of the HUNCHEST screening program , 2022, European Radiology.

[6]  M. Mansour,et al.  Therapeutic targeting of “undruggable” MYC , 2021, EBioMedicine.

[7]  P. Iyengar,et al.  Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[8]  Jing Wang,et al.  Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer , 2021, Cancer & Metabolism.

[9]  Y. Pommier,et al.  Molecular Subtypes of Primary Small Cell Lung Cancer Tumors and Their Associations with Neuroendocrine and Therapeutic Markers. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  Y. Lou,et al.  Targeted therapy in advanced non-small cell lung cancer: current advances and future trends , 2021, Journal of Hematology & Oncology.

[11]  J. Whitfield,et al.  The long journey to bring a Myc inhibitor to the clinic , 2021, The Journal of cell biology.

[12]  J. Qin,et al.  MYCL1 Amplification and Expression of L-Myc and c-Myc in Surgically Resected Small-Cell Lung Carcinoma , 2021, Pathology & Oncology Research.

[13]  C. Rudin,et al.  Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  W. Klepetko,et al.  Molecular profiles of small cell lung cancer subtypes: therapeutic implications , 2021, Molecular therapy oncolytics.

[15]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[16]  G. Botti,et al.  Surgery in Small-Cell Lung Cancer , 2021, Cancers.

[17]  P. Robson,et al.  Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. , 2021, Cancer cell.

[18]  P. Demertzis,et al.  Multidisciplinary care models for patients with lung cancer , 2020, Breathe.

[19]  David R. Jones,et al.  Predictors of survival following surgical resection of limited-stage small cell lung cancer. , 2020, The Journal of thoracic and cardiovascular surgery.

[20]  Joseph B Hiatt,et al.  MYCN drives chemoresistance in small cell lung cancer while USP7 inhibition can restore chemosensitivity , 2020, Genes & development.

[21]  Gabor Marth,et al.  MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate. , 2020, Cancer cell.

[22]  Ma-wei Jiang,et al.  Prognostic significance of C-MYC dysregulation in esophageal squamous cell carcinoma: a meta-analysis. , 2020, Biomarkers in medicine.

[23]  Christine Y. Lu,et al.  Lung cancer survival and mortality in Taiwan following the initial launch of targeted therapies: an interrupted time series study , 2020, BMJ Open.

[24]  Harry J de Koning,et al.  Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. , 2020, The New England journal of medicine.

[25]  R. Hoffman,et al.  Myc is a prognostic biomarker and potential therapeutic target in osteosarcoma , 2020, Therapeutic advances in medical oncology.

[26]  Xiaofeng Pei,et al.  Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer , 2019, Journal of Cancer Research and Clinical Oncology.

[27]  Nicholas T. Ingolia,et al.  MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion , 2019, Clinical Cancer Research.

[28]  C. Rudin,et al.  Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data , 2019, Nature Reviews Cancer.

[29]  H. Stein,et al.  MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients , 2018, Haematologica.

[30]  W. Klepetko,et al.  Controversies in oncology: surgery for small cell lung cancer? It’s time to rethink the case , 2018, ESMO Open.

[31]  Roman K. Thomas,et al.  Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. , 2018, Cancer discovery.

[32]  G. Qing,et al.  Targeting oncogenic Myc as a strategy for cancer treatment , 2018, Signal Transduction and Targeted Therapy.

[33]  Yan Yan,et al.  MYC overexpression with its prognostic and clinicopathological significance in breast cancer , 2017, Oncotarget.

[34]  M. Sos,et al.  Family matters: How MYC family oncogenes impact small cell lung cancer , 2017, Cell cycle.

[35]  J. Li,et al.  Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages , 2017, Scientific Reports.

[36]  Kristofer C. Berrett,et al.  MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. , 2017, Cancer cell.

[37]  M. Berry,et al.  Role of Adjuvant Therapy in a Population-Based Cohort of Patients With Early-Stage Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Florenza Lüder Ripoli,et al.  A Comparison of Fresh Frozen vs. Formalin-Fixed, Paraffin-Embedded Specimens of Canine Mammary Tumors via Branched-DNA Assay , 2016, International journal of molecular sciences.

[39]  J. Yokota,et al.  Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation , 2016, Oncotarget.

[40]  F. de Marinis,et al.  Cellular and molecular biology of small cell lung cancer: an overview. , 2016, Translational lung cancer research.

[41]  E. Miyaoka,et al.  Surgery for Small Cell Lung Cancer: A Retrospective Analysis of 243 Patients from Japanese Lung Cancer Registry in 2004 , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[42]  R. Meurer,et al.  MYC amplification is associated with poor survival in small cell lung cancer: a chromogenic in situ hybridization study , 2014, Journal of Cancer Research and Clinical Oncology.

[43]  M. Oberley,et al.  Immunohistochemical evaluation of MYC expression in mantle cell lymphoma , 2013, Histopathology.

[44]  H. Kim,et al.  Surgical Outcomes in Small Cell Lung Cancer , 2012, The Korean journal of thoracic and cardiovascular surgery.

[45]  A. Ariza,et al.  Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas , 2011, Histopathology.

[46]  G. Kalemkerian,et al.  Small cell lung cancer , 2010, Seminars in Respiratory and Critical Care Medicine.

[47]  R. Stephens,et al.  The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  Herbert S Schwartz,et al.  Prognostic significance of c-Myc expression in soft tissue leiomyosarcoma , 2009, Modern Pathology.

[49]  L. Penn,et al.  Reflecting on 25 years with MYC , 2008, Nature Reviews Cancer.

[50]  S. Jabbour,et al.  Current state of immunotherapy for non-small cell lung cancer. , 2007, Translational lung cancer research.

[51]  J. Sastre,et al.  Why females live longer than males: control of longevity by sex hormones. , 2005, Science of aging knowledge environment : SAGE KE.

[52]  H. Kato,et al.  Outcome of surgery for small cell lung cancer -- response to induction chemotherapy predicts survival. , 2004, The Thoracic and cardiovascular surgeon.

[53]  D. Liao,et al.  Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses , 2004, British Journal of Cancer.

[54]  B. Trock,et al.  C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance , 2000, British Journal of Cancer.

[55]  D. Boffa,et al.  Defining outcomes of patients with clinical stage I small cell lung cancer upstaged at surgery. , 2017, Lung cancer.